Your browser doesn't support javascript.
loading
Guiding bispecific monovalent antibody formation through proteolysis of IgG1 single-chain.
Dimasi, Nazzareno; Fleming, Ryan; Sachsenmeier, Kris F; Bezabeh, Binyam; Hay, Carl; Wu, Jincheng; Sult, Erin; Rajan, Saravanan; Zhuang, Li; Cariuk, Peter; Buchanan, Andrew; Bowen, Michael A; Wu, Herren; Gao, Changshou.
Afiliação
  • Dimasi N; a Antibody Discovery and Protein Engineering, MedImmune , Gaithersburg , MD , USA.
  • Fleming R; a Antibody Discovery and Protein Engineering, MedImmune , Gaithersburg , MD , USA.
  • Sachsenmeier KF; b Translational Sciences, IMED Oncology AstraZeneca , Waltham , MA , USA.
  • Bezabeh B; a Antibody Discovery and Protein Engineering, MedImmune , Gaithersburg , MD , USA.
  • Hay C; c Oncology Research, MedImmune , Gaithersburg , MD , USA.
  • Wu J; d Research Bioinformatics, MedImmune , Gaithersburg , MD , USA.
  • Sult E; c Oncology Research, MedImmune , Gaithersburg , MD , USA.
  • Rajan S; a Antibody Discovery and Protein Engineering, MedImmune , Gaithersburg , MD , USA.
  • Zhuang L; a Antibody Discovery and Protein Engineering, MedImmune , Gaithersburg , MD , USA.
  • Cariuk P; e Antibody Discovery and Protein Engineering, MedImmune , Cambridge , UK.
  • Buchanan A; e Antibody Discovery and Protein Engineering, MedImmune , Cambridge , UK.
  • Bowen MA; a Antibody Discovery and Protein Engineering, MedImmune , Gaithersburg , MD , USA.
  • Wu H; a Antibody Discovery and Protein Engineering, MedImmune , Gaithersburg , MD , USA.
  • Gao C; a Antibody Discovery and Protein Engineering, MedImmune , Gaithersburg , MD , USA.
MAbs ; 9(3): 438-454, 2017 04.
Article em En | MEDLINE | ID: mdl-28055299
ABSTRACT
We developed an IgG1 domain-tethering approach to guide the correct assembly of 2 light and 2 heavy chains, derived from 2 different antibodies, to form bispecific monovalent antibodies in IgG1 format. We show here that assembling 2 different light and heavy chains by sequentially connecting them with protease-cleavable polypeptide linkers results in the generation of monovalent bispecific antibodies that have IgG1 sequence, structure and functional properties. This approach was used to generate a bispecific monovalent antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor that 1) can be produced and purified using standard IgG1 techniques; 2) exhibits stability and structural features comparable to IgG1; 3) binds both targets simultaneously; and 4) has potent anti-tumor activity. Our strategy provides new engineering opportunities for bispecific antibody applications, and, most importantly, overcomes some of the limitations (e.g., half-antibody and homodimer formation, light chains mispairing, multi-step purification), inherent with some of the previously described IgG1-based bispecific monovalent antibodies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunoglobulina G / Engenharia de Proteínas / Anticorpos Biespecíficos / Anticorpos de Cadeia Única Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunoglobulina G / Engenharia de Proteínas / Anticorpos Biespecíficos / Anticorpos de Cadeia Única Idioma: En Ano de publicação: 2017 Tipo de documento: Article